From: Novel group-based QSAR and combinatorial design of CK-1δ inhibitors as neuroprotective agents
Compound | R1 | R2 | R3 | R4 | R5 | R6 | IC_{50} |
---|---|---|---|---|---|---|---|
1 | H | Me | H | Cl | H | H | 0.083 |
2 | H | CF_{3} | H | Cl | H | H | 0.023 |
3 | H | OMe | H | Cl | H | H | 0.53 |
4 | H | OCF_{3} | H | Cl | H | H | 0.54 |
5 | H | OEt | H | Cl | H | H | 1.21 |
6 | H | CF_{3} | Cl | H | H | H | 0.068 |
7 | H | OMe | Cl | H | H | H | 9.71 |
8 | H | OEt | Cl | H | H | H | 17.43 |
9 | H | CF_{3} | H | H | Cl | H | 0.065 |
10 | H | OMe | H | H | Cl | H | 0.75 |
11 | H | OEt | H | H | Cl | H | 1.11 |
12 | H | Br | OMe | H | H | H | 0.26 |
13 | H | Cl | OMe | H | H | H | 0.32 |
14 | H | F | OMe | H | H | H | 1.17 |
15 | H | Me | OMe | H | H | H | 0.29 |
16 | H | OMe | OMe | H | H | H | 2.22 |
17 | H | OCF_{3} | OMe | H | H | H | 0.62 |
18 | H | OEt | OMe | H | H | H | 5.76 |
19 | H | CF_{3} | H | OMe | H | H | 0.042 |
20 | H | OMe | H | OMe | H | H | 0.42 |
21 | H | OEt | H | OMe | H | H | 0.99 |
22 | H | CF_{3} | H | CF_{3} | H | H | 0.087 |
23 | H | CF_{3} | H | H | OMe | H | 0.033 |
24 | H | OMe | H | H | OMe | H | 0.57 |
25 | H | OEt | H | H | OMe | H | 1.09 |
26 | H | H | H | H | H | H | 0.33 |
27 | H | CF_{3} | H | H | H | H | 0.047 |
28 | H | CF_{3} | H | Cl | Cl | H | 0.056 |
29 | H | OMe | H | Cl | Cl | H | 1.24 |
30 | H | OEt | H | Cl | Cl | H | 3.43 |
31 | H | OCF_{3} | H | Cl | Cl | H | 0.59 |
32 | H | CF_{3} | OMe | H | H | OMe | 0.19 |
33 | H | OCF_{3} | H | OMe | OMe | OMe | 0.079 |
34 | H | OMe | H | OMe | OMe | OMe | 1.12 |
35 | H | OEt | H | OMe | OMe | OMe | 1.43 |
36 | H | CF_{3} | H | OMe | OMe | OMe | 0.015 |
37 | H | H | H | Cl | H | H | 0.85 |